Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs BLI 489 (Primary)
- Indications Bacterial infections; Urinary tract infections
- Focus Adverse reactions
- 09 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from not yet recruiting to recriuting as reported by ClinicalTrials.gov.
- 16 Jun 2009 Location (USA) identified as reported by ClinicalTrials.gov.